Introduction: N-Acetylcysteine (NAC) has been used to treat paracetamol overdose for four decades. But the administration of NAC regimens is complicated. Therefore, medication errors are an ongoing issue in the acute-care setting and directly impact the safety of patients. Objective: To evaluate the rate of NACrelated medication errors during the management of paracetamol overdose at a teaching hospital in Malaysia. Methods: This clinical audit study was performed retrospectively between June 2008 and June 2011. Patients who presented to the adult emergency department with paracetamol overdose and had received at least the loading dose of intravenous NAC were eligible. Children below the age of 12 years old were not included. Also, patients displaying chronic excessive paracetamol usage or recurrent paracetamol overdose were excluded. We determined the type and frequency of medication errors during intravenous NAC administration. Results: The study population ranged from 13 to 87 years old (mean age: 25.06; median: 23) and was predominantly female. The overall prevalence of intravenous NAC-related medication errors was found to be 84.3%. Moreover, the following frequencies were observed based on error type: 5.9% wrong dose, 37.3% incorrect infusion rate, 8.5% interruption during treatment, and 66.5% unnecessary administration. Conclusion: We observe a surprisingly high prevalence of medication errors related to the administration of intravenous NAC. Thus, this emerging issue needs be addressed in order to ensure patient safety as well as to prevent unnecessary hospital admissions and/or burdening treatment costs. (Hong Kong
Introduction
Paracetamol (acetyl-para-aminophenolor APAP) is a commonly utilised antipyretic and analgesic agent in Malaysia. In addition, it is the most frequently ingested drug in cases of poisoning within the United States, the United Kingdom, and several European countries. 1, 2 In fact, the mortality rate associated with paracetamol overdose has increased to approximately 500 deaths per year in England and Wales. 3, 4 In addition, demographic data from Malaysia has indicated that approximately 41% of the poisoning cases presenting to emergency departments were due to paracetamol overdose. 5 Data from both the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) and the Acute Liver Failure Study Group (ALFSG) have d emo n st r a t ed t h at t h e med ia n d a ily do s e o f paracetamol associated with liver injury is 5 to 7.5 g/ day, which is close to the current maximum daily dose (4 g/day). Moreover, there have been reports of liver failure occurring with paracetamol ingestion below 7.5 g. 6, 7 Intravenous N-Acetylcysteine (NAC) is an effective antidote for paracetamol overdose. There are several published protocols for NAC administration, which vary in length of treatment from 20 to 72 hours; however, the 20-hour protocol is the most widely accepted. 8 The 20-hour regimen is complex because it consists of three distinct doses, which require different calculatio ns, dilutio ns, and ra tes of a dmin ist ra tio n. Th us , th is co mplic at ed NAC delivery protocol is associated with a high potential fo r medicat io n erro r. Fur thermo re, f ollowing the 20-hour regimen, additional doses are often considered if blood tests indicate acidaemia, altered l iv e r e n z y me s , i n c r ea s e d p r o t h ro m b i n t i me / i n t e r n a t i o n a l n o r m a l is e d r a t i o ( I N R ) , r en a l dysfunction, or encephalopathy.
In the 20-hour protocol, NAC is administered at a loading dose of 150 mg/kg over 15 minures. NAC is then infused at 50 mg/kg over 4 hours, which is followed by a final dose that is infused at 100 mg/kg over 16 hours. After reviewing many retrospective studies regarding intravenous NAC protocols, Rowden et al concluded that when NAC was initiated within 8 hours of ingestion, no protocol was more advantageous than others. 8 Also, a study by Merl et al reported that there were diverse rates (4-48%) of adverse drug reactions associated with the use of NAC for treating paracetamol overdose. 9 Medication errors are preventable events that can lead to inappropriate use of medicines and/or harm to patients. Mistakes can occur during any of the following processes: prescribing, ordering, dispensing, distribution, preparation, administration, labelling, packaging, nomenclature, communication, education, use, and treatment monitoring. 10 Obser vational studies have demonstrated that medication error rates within the acute-care setting varied between 14.9% and 32.4%. Moreover, medication error rates associated with intravenous medications are known to be significantly higher in comparison to other administration routes, with reports indicating drug preparation error rates of 26% and administration error rates of 34%.
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Treatment of paracetamol overdose should not compromise patient safety or the healthcare system. Although most studies have indicated that NAC is a safe drug with non-fatal adverse reactions, one fatal case of myocardial infarction associated with errors in intravenous NAC administration was reported. 12 不必要給藥。結論：我們觀察到 NAC 靜脈注射給藥的令人驚訝的高用藥錯誤率。因此，這種新出現的 問題需要得到解決，以確保患者的安全，以及防止不必要的住院或治療費用。 Keywords: Human, overdose, patient safety, risk management
關鍵詞：人類、過量、病人安全、風險管理
The aim of this study was to evaluate the rate of NACrelated medication errors during the management of paracetamol overdose at a teaching hospital in Malaysia.
Methods
This clinical audit study was conducted in the adult Trauma and Emergency Department at the University Malaya Medical Center, which is a 900-bed teaching hospital in Kuala Lumpur. Data were collected retrospectively from the medical record department. Patients who had received at least the loading dose of intravenous NAC for paracetamol overdose were eligible. Children below the age of 12 years old were not included. In addition, patients displaying chronic excessive paracetamol usage or recurrent paracetamol overdose were excluded.
A standard Rumack-Matthew nomogram was used to determine whether NAC therapy would be initiated or continued. In brief, a logarithmic graph was created plotting paracetamol serum concentration against time. A curved line was drawn to connect points corresponding to 200 mg/L at 4 hours after ingestion and 6.25 mg/L at 24 hours post ingestion (i.e., the normal-risk treatment line). A high-risk treatment line was also established, which was plotted lower than the normal treatment line (using 100 mg/L at 4 hours) ( Figure 1 ).
Discontinuation of intravenous NAC after completion of the three doses (20 hours) was based on the following criteria: paracetamol level <10 mg/L, normal aminotransferase level, INR <2, normal serum creatinine, and serum bicarbonate >20 mEq/L. 13 Data entry and statistical analysis were performed using Statistical Package for Social Studies (SPSS) software (version 18.0). Data were used to analyse the frequency of NAC administration errors, including incorrect dose, incorrect infusion rate, interruption of therapy for >1 hour, and unnecessary administration.
Results
The study population has an age ranged from 13 to 87 years old and it was predominantly young adult females (mean age: 25.06; median: 23) (Figure 2 ). Total dose of paracetamol ingestion ranged from 1.5-55 g (i.e., 3-110 tablets [500 mg formulation]). We found that 33.5% (n=79) of the patients presented to the emergency department within 3-4 hours post ingestion, whereas 24.6% (n=58) went to the hospital late (>8 hours after ingestion).
During the study period, a total of 271 patients were labeled as paracetamol overdoses; however, only 236 of these cases fulfilled the criteria for inclusion in our investigation (Table 1) . Therefore, 35 cases were excluded: 26 cases were not started on NAC due to subtoxic paracetamol levels, four cases were not administered NAC despite toxic paracetamol levels, t h ree c a s es were g iven N AC wit h o u t p ro p er documentation, one case ingested paracetamol multiple times within a 24-hour period, and one case was treated using the 48-hour NAC protocol.
Additionally, 11 cases had not ingested >4 g of paracetamol, and therefore did satisfy the definition of "overdose". In fact, only one case from this subgroup displayed a paracetamol plasma level above the treatment line on the Rumack-Matthew nomogram, but they all received intravenous NAC treatment. Moreover, we found that numerous cases showed multiple errors occurring within a single treatment regimen. Overall, 84.3% (n=199) of the cases involved either single or multiple errors during NAC administration. Strikingly, only 15.7% (n=37) of the patients were given an intravenous NAC regimen without error.
The serum concentration of paracetamol was plotted against time in order to create a standard RumackMatthew nomogram, which consisted of a curved line connecting points corresponding to 200 mg/L at 4 hours post ingestion and 6.25 mg/L at 24 hours after ingestion. Using this graph, we found that 61.9% (n=146) of patients had received intravenous NAC despite paracetamol plasma levels that were below the treatment line.
Errors in NAC dose calculation or preparation were found in 14 samples (5.9%). In fact, our findings indicated that the most common dose errors occurred during the third dose of NAC (3.8%), which were followed by first dose (2.1%) and second dose (1.3%) errors. Furthermore, rate administration errors of NAC were found in 88 cases (37.3%). Again, the data revealed that many patients had multiple rate administration errors within one treatment regimen. The highest incidence (22.9%) of infusion rate error was observed at the second dose, followed by first dose (15.7%), and third dose (13.6%) errors. For 2.5% (n=6) of the cases, we found that infusion rates could not be determined due to unclear instructions and poor documentation ( Table 2 ).
Interruption of drug administration for >1 hour during NAC treatment occurred in 5.5% of the cases. In addition, we observed that in 1.3% (n=3) of this subgroup, NAC was stopped prior to completion of t h e 2 0 -h o u r p ro t o c o l. In t er r u p t io n o f N AC administration due to adverse drug reactions was not included in this result.
Unnecessary administration of intravenous NAC was found in 66.5% (n=157) of the cases. In fact, approximately 40.7% (n=96) of the patients received intravenous NAC despite subtoxic paracetamol plasma levels and normal liver function. For 16.5% (n=39), treatment was initiated prior to obtaining a subtoxic paracetamol plasma result at 4 hours. Also, we found that unnecessary continuation of treatment beyond 20 hours occurred in 17.8% (n=42) of cases.
The prevalence of adverse effects during NAC administration was 11.4% (n=27). However, no fatal reactions were noted in this study. The most commonly reported side effects were rashes, urticaria, and vomiting. Notably, one patient developed chest tightness and hypotension. These adverse reactions to NAC were dealt with in the following ways: 12 cases (44%) required that the infusion rate be slowed down or stopped temporarily, eleven cases (41%) stopped treatment totally, and four cases (15%) received oral methionine as a replacement therapy.
Discussion
The frequency of medication errors during intravenous NAC administration at our center was surprisingly high LFT=liver function test (84.3%; n=199). Our findings indicated that incorrect dosing accounted for 5.9% of the errors, occurring mainly during the NAC dilution process. Therefore, making weight-based NAC dosing charts available in the emergency department may constitute an effective preventative measure. 14 Although we found the prevalence of infusion rate errors and interruption of NAC administration to be quite high in our study, the relation of this finding to clinical outcome remains to be determined. These mistakes occurred as a result of manual rate calculation errors during intravenous NAC administration and variation in nursing practices. Indeed, some of the junior nursing staff was not familiar with the NAC regimen. Also, we calculated a nurse-patient ratio of 1:4 in our acute-care setting, which increased to 1:5 during periods of crowding. This factor likely contributed to infusion rate error or interruption of NAC administration. Therefore, providing more infusion pumps could represent a logical way to minimise infu sion rate errors a nd/or th erapy interruption, as these devices allow automatic and accurate rate control. In addition, these pumps could be re-used for other purposes.
Unnecessary NAC administration was the most common type of error observed in our study (66.5%). Although a previous report demonstrated a relatively small rate of hepatotoxicity due to paracetamol overdose in the Asian population, 15 the threshold used in our center for starting intravenous NAC was low. Indeed, our observed error prevalence was much greater than that shown in a study by Hayes, which indicated that errors associated with intravenous NAC during treatment of paracetamol overdose occurred in only one-third of cases and most frequently involved interruption in therapy for >1 hour. 16 Unfortunately, this study found that 61.9% (n=146) of cases fell below the treatment line based on the Rumack-Matthew nomogram. In fact, all patients in our study had received at least the loading dose of NAC, which indicates that NAC was liberally given to anyone who presented with paracetamol overdose. This practice, which put patients at unnecessary risk, likely stemmed from two factors. First, there was no official department policy in place regarding when to initiate NAC administration. Patients with significant paracetamol ingestion (10 g) were started on intravenous NAC prior to knowing the paracetamol plasma level and ingestion time. Secondly, there was confusion regarding how to interpret the normal-risk (200 mg/L) and high-risk (100 mg/L) treatment lines of the Rumack-Matthew nomogram based on the reference information provided in the emergency department. Thus, the patients' risk stratification for paracetamol overdose was rarely considered before starting NAC therapy. Even though the majority of cases did not fall within the high-risk group, they were commonly treated as high-risk patients.
The threshold that should be used for starting NAC therapy based on the Rumack-Matthew nomogram remains controversial. In fact, a 25% reduction from the original paracetamol plasma concentration cut-off (i.e., 200 mg/L to 150 mg/L at 4 hours) was introduced to accommodate potential errors in obtaining exact ingestion times or laboratory results. 17 The United Kingdom guidelines still require the use of the original nomogram criteria because the absolute risk of hepatotoxicity has not been clearly established for the revised standard, and it remains unclear whether the benefits of treatment between 150 and 200 mg/L outweigh the risks. 18 United States, Australia, and New Zealand use the 150 mg/L threshold because there is evidence to suggest that there is only a 1% hepatotoxicity incidence in patients with this paracetamol level, and all patients recovered without any complications. In addition, some have argued that use of a single treatment line (150 mg/L) avoids the potential confusion associated with an additional line. Also, we found an 11.4% (n=27) incidence of adverse reactions (e.g., allergy) during NAC administration. Most commonly these reactions were characterised by rashes, urticaria, and vomiting. However, no fatal side effects were noted in this study. These results are in accordance with those obtained in an Australian study, which reported that 11.2% of cases involving NAC-treated acetaminophen overdose yielded adverse reactions.
There were some key limitations during this study. For example, data collection was sometimes incomplete because the primary source of information was the emergency department registration book, which was not entirely available for the last three years (2008) (2009) (2010) (2011) . In addition, the reporting system for medication errors used in this study has not yet been validated by the hospital quality unit. This could result in potential information biases due to over or under reporting of certain events. Finally, this study was conducted retrospectively, and did not account for the fact that past practices may have changed over time.
Conclusion
Compared to similar studies, we observe a surprisingly high prevalence of medication errors related to the administration of intravenous NAC. Thus, this emerging issue needs be addressed in order to ensure patient safety as well as to prevent unnecessary hospital admissions and/or burdening treatment costs.
